Hematopoietic cell transplantation for blood cancer patients living with HIV in Taiwan - A case series

Yi-Wei Lee; Eve Chen; Yi-Ting Chuang; Wei-Li Ma; Shang-Ju Wu

doi:10.1016/j.jfma.2024.12.002

Hematopoietic cell transplantation for blood cancer patients living with HIV in Taiwan - A case series

J Formos Med Assoc. 2024 Dec 7:S0929-6646(24)00561-8. doi: 10.1016/j.jfma.2024.12.002. Online ahead of print.

Authors

Yi-Wei Lee¹, Eve Chen², Yi-Ting Chuang³, Wei-Li Ma⁴, Shang-Ju Wu⁵

Affiliations

¹ Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
² Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; University of California, Davis, Davis, CA, USA.
³ Department of Medical Education and Research, Mennonite Christian Hospital, Hualien, Taiwan.
⁴ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
⁵ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: [email protected].

PMID: 39648100
DOI: 10.1016/j.jfma.2024.12.002

Abstract

People living with HIV (PLWH) have an increased risk of developing cancers, especially hematologic malignancies (HM). Hematopoietic stem cell transplantation (HSCT) has been an important treatment modality for patients with HM. However, the experience of HSCT in PLWH with HM remains limited in Asia. Therefore, we describe a case series of PLWH treated with HSCT in Taiwan. In these PLWH patients, HSCT procedures, either autologous (auto-HSCT) or allogeneic (allo-HSCT), were feasible with acute toxicity profiles comparable to those in non-HIV patients. However, auto-HSCT seemed unable to lead toward durable remission in PLWH with relapsed/refractory lymphoma, implicating that allo-HSCT might warrant early considerations for consolidation purposes in this distinct patient group.

Publication types

Case Reports